Top

Published in:

01-02-2010 | Review and Perspective

Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers

Authors: Andrew H. Beck, Robert B. West, Matt van de Rijn

Published in: Virchows Archiv | Issue 2/2010

Abstract

Soft tissue sarcomas are malignant neoplasms derived from mesenchymal tissues. Their pathogenesis is poorly understood and there are few effective treatment options for advanced disease. In the past decade, gene expression profiling has been applied to sarcomas to facilitate understanding of sarcoma pathogenesis and to identify diagnostic, prognostic, and predictive markers. In this paper, we review this body of work and discuss how gene expression profiling has led to advancements in the understanding of sarcoma pathobiology, the identification of clinically useful biomarkers, and the refinement of sarcoma classification schemes. Lastly, we conclude with a discussion of strategies to further optimize the translation of gene expression data into a greater understanding of sarcoma pathogenesis and improved clinical outcomes for sarcoma patients.

Weiss SW, Goldblum JR (2008) Enzinger and Weiss’s soft tissue tumors, 5th edn. Mosby/Elsevier, Philadelphia

Fletcher CDM, Unni KK, Mertens F et al (2002) Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon

Wendtner CM, Abdel-Rahman S, Krych M et al (2002) Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 20:3156–3164CrossRefPubMed

O’Sullivan B, Davis AM, Turcotte R et al (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359:2235–2241CrossRefPubMed

Borden EC, Baker LH, Bell RS et al (2003) Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 9:1941–1956PubMed

Judson I (2008) State-of-the-art approach in selective curable tumours: soft tissue sarcoma. Ann Oncol 19(Suppl 7):vii166–vii169CrossRefPubMed

Schena M, Shalon D, Davis RW et al (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467–470CrossRefPubMed

Brown PO, Botstein D (1999) Exploring the new world of the genome with DNA microarrays. Nat Genet 21:33–37CrossRefPubMed

Lockhart DJ, Winzeler EA (2000) Genomics, gene expression and DNA arrays. Nature 405:827–836CrossRefPubMed

10.

Fodor SP, Rava RP, Huang XC et al (1993) Multiplexed biochemical assays with biological chips. Nature 364:555–556CrossRefPubMed

11.

Allison DB, Cui X, Page GP et al (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7:55–65CrossRefPubMed

12.

Butte A (2002) The use and analysis of microarray data. Nat Rev Drug Discov 1:951–960CrossRefPubMed

13.

Rhodes DR, Chinnaiyan AM (2004) Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann N Y Acad Sci 1020:32–40CrossRefPubMed

14.

Rhodes DR, Kalyana-Sundaram S, Tomlins SA et al (2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9:443–454CrossRefPubMed

15.

Segal E, Friedman N, Kaminski N et al (2005) From signatures to models: understanding cancer using microarrays. Nat Genet 37(Suppl):S38–S45CrossRefPubMed

16.

Potti A, Dressman HK, Bild A et al (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294–1300CrossRefPubMed

17.

Tschoep K, Kohlmann A, Schlemmer M et al (2007) Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63:111–124CrossRefPubMed

18.

Eilber FC, Dry SM (2008) Diagnosis and management of synovial sarcoma. J Surg Oncol 97:314–320CrossRefPubMed

19.

Clark J, Rocques PJ, Crew AJ et al (1994) Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7:502–508CrossRefPubMed

20.

Kawai A, Woodruff J, Healey JH et al (1998) SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338:153–160CrossRefPubMed

21.

Haldar M, Randall RL, Capecchi MR (2008) Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res 466:2156–2167CrossRefPubMed

22.

Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301–1307CrossRefPubMed

23.

Nakayama R, Nemoto T, Takahashi H et al (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749–759CrossRefPubMed

24.

Baird K, Davis S, Antonescu CR et al (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65:9226–9235CrossRefPubMed

25.

Segal NH, Pavlidis P, Antonescu CR et al (2003) Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163:691–700PubMed

26.

Allander SV, Illei PB, Chen Y et al (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161:1587–1595PubMed

27.

Francis P, Namlos HM, Muller C et al (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73CrossRefPubMed

28.

Nagayama S, Katagiri T, Tsunoda T et al (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62:5859–5866PubMed

29.

Henderson SR, Guiliano D, Presneau N et al (2005) A molecular map of mesenchymal tumors. Genome Biol 6:R76CrossRefPubMed

30.

Nielsen TO, Hsu FD, O’Connell JX et al (2003) Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 163:1449–1456PubMed

31.

Terry J, Saito T, Subramanian S et al (2007) TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31:240–246CrossRefPubMed

32.

Barco R, Hunt LB, Frump AL et al (2007) The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Mol Biol Cell 18:4003–4012CrossRefPubMed

33.

Lee YF, John M, Edwards S et al (2003) Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 88:510–515CrossRefPubMed

34.

Fernebro J, Francis P, Eden P et al (2006) Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118:1165–1172CrossRefPubMed

35.

Ladanyi M, Antonescu CR, Leung DH et al (2002) Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62:135–140PubMed

36.

Guillou L, Benhattar J, Bonichon F et al (2004) Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22:4040–4050CrossRefPubMed

37.

Takenaka S, Ueda T, Naka N et al (2008) Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 19:467–476PubMed

38.

Ray-Coquard I, Le Cesne A, Whelan JS et al (2008) A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 13:467–473CrossRefPubMed

39.

Lubieniecka JM, de Bruijn DR, Su L et al (2008) Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 68:4303–4310CrossRefPubMed

40.

Lee YF, John M, Falconer A et al (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201–7204CrossRefPubMed

41.

Lee CH, Espinosa I, Vrijaldenhoven S et al (2008) Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 14:1423–1430CrossRefPubMed

42.

Dei Tos AP (2000) Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol 4:252–266CrossRefPubMed

43.

Singer S, Socci ND, Ambrosini G et al (2007) Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626–6636CrossRefPubMed

44.

Sirvent N, Coindre JM, Maire G et al (2007) Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 31:1476–1489CrossRefPubMed

45.

Matushansky I, Hernando E, Socci ND et al (2008) A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 172:1069–1080CrossRefPubMed

46.

Tos AP (2006) Classification of pleomorphic sarcomas: where are we now? Histopathology 48:51–62CrossRef

47.

Ozzello L, Stout AP, Murray MR (1963) Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 16:331–344CrossRefPubMed

48.

Fletcher CD (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213–228PubMedCrossRef

49.

Fletcher CD, Gustafson P, Rydholm A et al (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19:3045–3050PubMed

50.

Fletcher CD (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48:3–12CrossRefPubMed

51.

Matushansky I, Hernando E, Socci ND et al (2007) Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117:3248–3257CrossRefPubMed

52.

Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130:1466–1478PubMed

53.

Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056CrossRefPubMed

54.

Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349CrossRefPubMed

55.

Sciot R, Debiec-Rychter M, Daugaard S et al (2008) Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer 44:1855–1860CrossRefPubMed

56.

Subramanian S, West RB, Corless CL et al (2004) Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23:7780–7790CrossRefPubMed

57.

West RB, Corless CL, Chen X et al (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165:107–113PubMed

58.

Espinosa I, Lee CH, Kim MK et al (2008) A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32:210–218CrossRefPubMed

59.

Yang YD, Cho H, Koo JY et al (2008) TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455:1210–1215CrossRefPubMed

60.

Price ND, Trent J, El-Naggar AK et al (2007) Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 104:3414–3419CrossRefPubMed

61.

Khan J, Wei JS, Ringner M et al (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673–679CrossRefPubMed

62.

Ohali A, Avigad S, Zaizov R et al (2004) Prediction of high risk Ewing’s sarcoma by gene expression profiling. Oncogene 23:8997–9006CrossRefPubMed

63.

Cheung IY, Feng Y, Danis K et al (2007) Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 13:6978–6983CrossRefPubMed

64.

Ferreira BI, Alonso J, Carrillo J et al (2008) Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing’s sarcoma. Oncogene 27:2084–2090CrossRefPubMed

65.

Hancock JD, Lessnick SL (2008) A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7:250–256PubMed

66.

Davicioni E, Finckenstein FG, Shahbazian V et al (2006) Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66:6936–6946CrossRefPubMed

67.

Ebauer M, Wachtel M, Niggli FK et al (2007) Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 26:7267–7281CrossRefPubMed

68.

Lae M, Ahn EH, Mercado GE et al (2007) Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 212:143–151CrossRefPubMed

69.

Wachtel M, Dettling M, Koscielniak E et al (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64:5539–5545CrossRefPubMed

70.

Ren YX, Finckenstein FG, Abdueva DA et al (2008) Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 68:6587–6597CrossRefPubMed

71.

Schaefer KL, Eisenacher M, Braun Y et al (2008) Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 44:699–709PubMed

72.

Linn SC, West RB, Pollack JR et al (2003) Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163:2383–2395PubMed

73.

West RB, Harvell J, Linn SC et al (2004) Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 28:1063–1069CrossRefPubMed

74.

Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the {beta}-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518–1527CrossRefPubMed

75.

Beck AH, Espinosa I, Gilks CB et al (2008) The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 88:591–601CrossRefPubMed

76.

West RB, Nuyten DS, Subramanian S et al (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3:e187CrossRefPubMed

77.

Bacac M, Migliavacca E, Stehle JC et al (2006) A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol 208:543–553CrossRefPubMed

78.

Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24:1195–1203CrossRefPubMed

79.

Kotiligam D, Lazar AJ, Pollock RE et al (2008) Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 23:117–126PubMed

80.

West RB, Rubin BP, Miller MA et al (2006) A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103:690–695CrossRefPubMed

81.

Murray LJ, Abrams TJ, Long KR et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757–766CrossRefPubMed

82.

Beck AH, Espinosa I, Edris B et al (2009) The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 15:778–787CrossRefPubMed

83.

Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210CrossRefPubMed

84.

Parkinson H, Sarkans U, Shojatalab M et al (2005) ArrayExpress—a public repository for microarray gene expression data at the EBI. Nucleic Acids Res 33:D553–D555CrossRefPubMed

85.

Bild AH, Potti A, Nevins JR (2006) Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6:735–741CrossRefPubMed

86.

Hu P, Bader G, Wigle DA et al (2007) Computational prediction of cancer-gene function. Nat Rev Cancer 7:23–34CrossRefPubMed

87.

Lamb J, Crawford ED, Peck D et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935CrossRefPubMed

88.

Lamb J (2007) The connectivity map: a new tool for biomedical research. Nat Rev Cancer 7:54–60CrossRefPubMed

89.

Dennis G Jr, Sherman BT, Hosack DA et al (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3CrossRefPubMed

90.

von Mering C, Jensen LJ, Kuhn M et al (2007) STRING 7—recent developments in the integration and prediction of protein interactions. Nucleic Acids Res 35:D358–D362CrossRef

91.

Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550CrossRefPubMed

92.

Segal E, Friedman N, Koller D et al (2004) A module map showing conditional activity of expression modules in cancer. Nat Genet 36:1090–1098CrossRefPubMed

93.

Rhodes DR, Yu J, Shanker K et al (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 101:9309–9314CrossRefPubMed

94.

Bonnefoi H, Potti A, Delorenzi M et al (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8:1071–1078CrossRefPubMed

95.

Dressman HK, Berchuck A, Chan G et al (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25:517–525CrossRefPubMed

96.

Subramanian S, Lui WO, Lee CH et al (2008) MicroRNA expression signature of human sarcomas. Oncogene 27:2015–2026CrossRefPubMed

97.

Camp RL, Neumeister V, Rimm DL (2008) A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 26:5630–5637CrossRefPubMed

Title: Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers
Authors: Andrew H. Beck
Robert B. West
Matt van de Rijn
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 2/2010
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-009-0774-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Gastrointestinal stromal tumors

Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations

Soft tissue sarcomas with complex genomic profiles

Genomic characteristics of soft tissue sarcomas

Running GAGs: myxoid matrix in tumor pathology revisited

Molecular pathology of sarcomas: concepts and clinical implications